Incyte Corporation (INCY)INCYIncyte Corporation

Financials

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	5.82B	1.67B	1.27B	1.51B	1.37B	1.22B	1.05B	1.18B	1.14B
Cost of Goods Sold	429.56M	104.96M	104.50M	121.10M	99.00M	78.80M	73.20M	88.50M	86.00M
Gross Profit	5.39B	1.57B	1.17B	1.39B	1.27B	1.14B	979.70M	1.09B	1.05B
Gross Profit Margin	92.6%	93.7%	91.8%	92.0%	92.8%	93.5%	93.0%	92.5%	92.4%
Total Operating Expenses	3.55B	871.18M	844.00M	1.00B	835.68M	825.92M	762.98M	792.83M	905.79M
Research & Development	2.15B	516.95M	515.90M	611.37M	506.58M	494.92M	437.28M	466.03M	573.17M
Selling, General & Administrative	1.40B	351.74M	328.10M	390.40M	329.10M	331.00M	325.70M	326.80M	309.20M
Operating Income (EBIT)	1.84B	697.90M	324.17M	383.96M	431.30M	310.81M	216.72M	297.36M	146.09M
Operating Margin	31.6%	41.7%	25.5%	25.5%	31.6%	25.6%	20.6%	25.2%	12.8%
Income Before Tax (EBT)	1.97B	751.51M	343.60M	389.94M	482.31M	558.01M	234.19M	313.72M	156.52M
Interest Income	129.34M	38.12M	33.69M	30.75M	26.78M	25.14M	22.93M	21.20M	N/A
Interest Expense	2.32M	581K	569K	582K	592K	594K	660K	419K	774K
Other Income/Expense	130.03M	53.62M	19.43M	5.98M	51.01M	247.20M	17.47M	16.36M	10.44M
Net Income	1.61B	585.61M	303.33M	299.28M	424.17M	405.00M	158.20M	201.21M	106.46M
Income Tax Expense	354.98M	165.91M	40.27M	90.66M	58.14M	153.01M	75.99M	112.51M	50.07M
Net Profit Margin	27.7%	35.0%	23.8%	19.9%	31.1%	33.3%	15.0%	17.1%	9.4%
EBITDA	1.94B	724.37M	347.98M	407.94M	455.32M	333.73M	239.08M	320.10M	168.60M
EBITDA Margin	33.3%	43.3%	27.3%	27.1%	33.3%	27.5%	22.7%	27.2%	14.8%
Depreciation & Amortization	98.28M	26.48M	23.80M	23.98M	24.02M	22.92M	22.36M	22.73M	22.52M
EPS Basic	8.13	2.92	1.52	1.52	2.17	2.09	0.82	1.04	0.55
EPS Diluted	7.85	2.81	1.47	1.46	2.11	2.04	0.80	1.02	0.54
Shares Outstanding	200.38M	200.38M	199.34M	197.44M	195.67M	194.00M	193.71M	193.15M	192.63M
Diluted Shares Outstanding	208.22M	208.22M	206.83M	204.77M	201.43M	198.74M	198.20M	197.42M	195.84M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	5.14B	4.24B	3.70B	3.39B	2.99B	2.67B	2.16B	1.88B
Cost of Goods Sold	372.10M	312.10M	254.99M	207.00M	150.99M	131.30M	114.25M	94.12M
Gross Profit	4.77B	3.93B	3.44B	3.19B	2.84B	2.54B	2.04B	1.79B
Gross Profit Margin	92.8%	92.6%	93.1%	93.9%	94.9%	95.1%	94.7%	95.0%
Total Operating Expenses	3.43B	3.83B	2.79B	2.60B	2.25B	2.80B	1.64B	1.66B
Research & Development	2.05B	2.61B	1.63B	1.59B	1.46B	2.22B	1.15B	1.20B
Selling, General & Administrative	1.38B	1.22B	1.16B	1.00B	739.56M	516.90M	468.71M	434.41M
Operating Income (EBIT)	1.34B	101.29M	655.36M	591.63M	585.78M	-263.68M	402.01M	129.22M
Operating Margin	26.1%	2.4%	17.7%	17.4%	19.6%	-9.9%	18.6%	6.9%
Income Before Tax (EBT)	1.66B	316.63M	834.22M	529.12M	570.44M	-232.22M	486.79M	115.35M
Interest Income	105.60M	128.71M	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	2.43M	2.28M	2.55M	2.67M	1.91M	2.17M	1.85M	1.54M
Other Income/Expense	321.66M	215.34M	178.86M	-62.51M	-15.33M	31.46M	84.78M	-13.88M
Net Income	1.29B	32.62M	597.60M	340.66M	948.58M	-295.70M	446.91M	109.49M
Income Tax Expense	377.80M	284.01M	236.62M	188.46M	-378.14M	63.48M	39.88M	5.85M
Net Profit Margin	25.0%	0.8%	16.2%	10.0%	31.8%	-11.1%	20.7%	5.8%
EBITDA	1.44B	190.54M	738.02M	659.48M	643.62M	-211.87M	456.54M	184.19M
EBITDA Margin	27.9%	4.5%	20.0%	19.4%	21.6%	-7.9%	21.1%	9.8%
Depreciation & Amortization	93.29M	89.25M	82.66M	67.86M	57.84M	51.81M	54.53M	54.97M
EPS Basic	6.59	0.16	2.67	1.53	4.30	-1.36	2.08	0.52
EPS Diluted	6.41	0.15	2.65	1.52	4.27	-1.36	2.05	0.51
Shares Outstanding	195.20M	207.11M	223.63M	222.00M	220.43M	218.07M	214.91M	212.38M
Diluted Shares Outstanding	200.70M	210.53M	225.93M	223.96M	222.07M	218.07M	217.66M	215.63M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.

Wilmington, DE

2,844 employees

www.incyte.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: William J. Meury

View full financials